Singapore markets closed

NightHawk Biosciences Inc (1HB.BE)

Berlin - Berlin Delayed price. Currency in EUR
Add to watchlist
0.1590+0.0030 (+1.92%)
At close: 08:30PM CEST
Full screen
Previous close0.1560
Open0.1520
Bid0.1420 x N/A
Ask0.1770 x N/A
Day's range0.1520 - 0.1600
52-week range0.1370 - 0.8400
Volume1,530
Avg. volume0
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date29 Apr 2024 - 05 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Scorpius Holdings Announces Receipt of Filing Delinquency Notification

    Reaffirms commitment to regaining compliance with the NYSE American continued listing standardsDURHAM, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), received an official notice of noncompliance (the “NYSE American Notice”) from NYSE Regulation stating that the Company is not in compliance with NYSE American LLC (“NYSE American” or the “Exchange”) continued listing standards (the “Fi

  • GlobeNewswire

    Scorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University

    DURHAM, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), today announced that it has been awarded a contract in excess of $1 million with an NIH-funded researcher at a major university. The program involves process optimization and development of a therapeutic antibody, which Scorpius will manufacture for preclinical studies. The work will be conducted in the Company’s state-of-the-art

  • GlobeNewswire

    Scorpius Holdings Accepted as a Member of the US Government’s BioMaP-Consortium

    Provides Access to Growth Funding and Enhanced Access to Federal ProjectsDURHAM, N.C., March 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), today announced that it has been accepted into the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), a part of the National Biopharmaceutical Manufacturing Partnership. The BioMap-Consortium has a $20 billion funding ceiling, throu